Boston Scientific stock: BTIG keeps USD 56.00 target for Boston Scientific stock
Published on 10/19/2026 at 15:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target precedes results
- BTIG reiterated its Buy rating and USD 56.00 target on October 12, 2026.
- Boston Scientific is scheduled to report third-quarter results on October 28, 2026.
- Boston Scientific stock costs EUR 39.41 at Lang & Schwarz on October 19, 2026 at 3:34 p.m. CEST.
- Boston Scientific had a trailing price-to-earnings ratio of 17.91 and market capitalization of USD 63.9 billion on October 19, 2026.
BTIG reiterated a Buy rating and a USD 56.00 price target for Boston Scientific on October 12, 2026, according to Markets Insider. Against the USD 44.08 NYSE price on October 19, 2026, that target stands 27.04 percent higher. Boston Scientific stock was trading at EUR 39.41 at Lang & Schwarz on October 19, 2026 at 3:34 p.m. CEST.
Revenue sets the earnings backdrop
Boston Scientific's second-quarter revenue reached USD 5.44 billion, while net profit came to USD 907.0 million for the quarter ended June 30, 2026. In the year-ago quarter, revenue was USD 5.06 billion and net profit was USD 793.0 million, according to Markets Insider. The figures put the upcoming report in a growth-oriented operating context without changing the focus on the target price.
Price range stays wide
On the NYSE, Boston Scientific was last at USD 44.08 on October 19, 2026 at 9:42 a.m. ET. The session range was USD 43.97 to USD 44.34, while trading volume reached 584,431 shares against an average of 19,719,032 shares.
The 52-week range was USD 41.39 to USD 105.65 on October 19, 2026. The NYSE price was 58.29 percent below the 52-week high and 6.50 percent above the low. Boston Scientific's market capitalization was USD 63.9 billion, with a trailing price-to-earnings ratio of 17.91.
Valuation and reporting date
Boston Scientific is scheduled to report third-quarter 2026 results on October 28, 2026, before the US market opens, according to MetaCap. The date gives investors a defined calendar point for testing whether the second-quarter revenue trajectory continued.
Comparison with peers
Boston Scientific (NYSE, USD): P/E 17.91, market capitalization USD 63.9 billion.
Abbott Laboratories (NYSE, USD): minus 0.44 percent, P/E 33.61, market capitalization USD 180.7 billion.
Medtronic (NYSE, USD): minus 0.24 percent, P/E 23.28, market capitalization USD 120.9 billion.
Boston Scientific stock in euros
The euro quotation remained the clearest Germany-facing market marker during the afternoon, while the US listing supplied the valuation and peer comparison. The next scheduled report on October 28, 2026 is the main date on the calendar.
The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.
Boston Scientific stock at a glance
- Company: Boston Scientific Corporation
- ISIN: US1011371077
- Ticker: BSX
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 19, 2026, 3:34 p.m. CEST): EUR 39.41
- Market capitalization: USD 63.9 billion (as of October 19, 2026)
- 52-week range: USD 41.39-105.65 (as of October 19, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: S&P 500
- Next earnings date: October 28, 2026
Market context: Market report S&P 500.
